Clinical Trial Update: ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo [Phase 2, Phase 3]

View source ↗

Summary

The ACTISAVE study evaluating glenzocimab as add-on therapy for acute ischemic stroke has completed its Phase 2/3 trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Glenzocimab (Glenzocimab)

Snippet

Sponsor: Acticor Biotech | Conditions: Acute Ischemic Stroke | Phase 2, Phase 3 | Status: COMPLETED